Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
News and updates for Precision BioSciences, Inc. (Nasdaq: DTIL) center on its progress as a clinical stage gene editing company using the ARCUS platform to develop in vivo therapies for serious genetic and infectious diseases. Company announcements frequently highlight developments in its pipeline, clinical trial milestones, scientific publications, and capital markets activity.
A major focus of Precision’s news flow is PBGENE-HBV, the company’s wholly owned in vivo gene editing program for chronic hepatitis B. Updates include data from the global ELIMINATE-B trial, covering safety, dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), and biopsy evidence of ARCUS-mediated viral DNA editing. Press releases also describe regulatory designations such as Breakthrough Therapy status and the expansion of clinical trial sites across multiple countries.
Another recurring theme is PBGENE-DMD, a muscle-targeted excision program for Duchenne muscular dystrophy. News items discuss preclinical data on dystrophin restoration and functional muscle improvement, preparations for investigational new drug (IND) submissions, and plans for Phase 1/2 clinical studies in DMD patients with mutations in exons 45–55 of the dystrophin gene.
Investors can also find updates on partnered in vivo programs, such as ECUR-506 for neonatal onset OTC deficiency developed by iECURE using a licensed ARCUS nuclease, along with regulatory milestones like RMAT designation. Additional coverage includes progress in non-core ex vivo programs such as azer-cel, an allogeneic CAR T therapy being advanced by partners for lymphoma and autoimmune diseases.
Financial and corporate news, including quarterly results, equity offerings, and strategic priorities, round out the DTIL news stream. For those tracking gene editing, hepatitis B, DMD, and ARCUS-based therapies, this page provides an organized view of Precision BioSciences’ latest disclosures and clinical developments over time.
iECURE (NASDAQ:DTIL) announced that ECUR-506, its investigational in vivo targeted gene insertion therapy for neonatal-onset ornithine transcarbamylase (OTC) deficiency, was selected for the FDA’s CMC Development and Readiness Pilot (CDRP) program.
Participation enables more frequent FDA engagement on CMC strategy ahead of a potential BLA, complements prior RMAT and Fast Track designations, and follows encouraging OTC-HOPE clinical data including a complete response in the first treated infant. Additional trial data is expected in H1 2026.
Precision BioSciences (Nasdaq: DTIL) reported Q4 and FY2025 results and provided clinical and corporate updates. Key highlights include PBGENE-HBV Phase 1 late-breaker data showing safety and dose-dependent antiviral activity, IND clearance for PBGENE-DMD in Feb 2026, and a $75M financing in Nov 2025.
The company ended 2025 with $137.2M cash, expects runway through 2028, reported Q4 revenue of $34.2M and full-year revenue of $34.3M, and received two patent Notices of Allowance extending PBGENE-HBV protection to Nov 2044.
Precision BioSciences (Nasdaq: DTIL) received two U.S. Notices of Allowance for patent applications covering its PBGENE-HBV program, including composition-of-matter claims for the PBGENE-HBV ARCUS nuclease and a novel shortened polypeptide linker.
When issued, each patent is expected to expire in November 2044, extending intellectual property protection for PBGENE-HBV and future ARCUS nucleases that use the linker.
Precision BioSciences (Nasdaq: DTIL) presented preclinical GLP data for PBGENE-DMD at the MDA Clinical & Scientific Conference 2026 showing durable dystrophin restoration and sustained functional benefit in a humanized DMD mouse model. Data include 50–65% reduction in CK at 90 days and sustained force output through nine months.
Findings report broad dystrophin-positive fibers in quadriceps, gastrocnemius, heart, and diaphragm and evidence of edited muscle satellite cells, supporting a one-time in vivo gene correction approach potentially applicable to ~60% of DMD patients.
Precision BioSciences (Nasdaq: DTIL) will publish fourth-quarter and fiscal 2025 financial results and deliver a business update on March 12, 2026. The company develops in vivo gene editing therapies using its proprietary ARCUS platform for high unmet-need diseases. Investors can expect results and management commentary on that date.
Precision BioSciences (Nasdaq: DTIL) announced the U.S. FDA granted Fast Track designation to PBGENE-DMD for treating Duchenne muscular dystrophy (DMD) and that it will host a virtual investor/KOL event on March 17, 2026 to discuss PBGENE-DMD and the planned Phase 1/2 FUNCTION-DMD study.
The company said Fast Track aims to facilitate development and expedite review, and noted recent IND clearance supporting PBGENE-DMD’s advancement toward clinical investigation in boys living with DMD.
Precision BioSciences (Nasdaq: DTIL) will receive $7.5 million from TG Therapeutics after a clinical milestone tied to a Phase 1 trial of azer-cel in progressive multiple sclerosis.
The proceeds consist of $5.25 million cash plus $2.25 million via purchase of 201,504 Precision shares at $11.17 per share. Precision said these funds, existing cash, and its ATM access are expected to provide runway through 2028.
Precision BioSciences (Nasdaq: DTIL) announced that new preclinical data for PBGENE-DMD was selected for a poster at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in Orlando, March 8-11, 2026.
The poster, titled "PBGENE-DMD gene editing treatment leads to safe and long-term functional improvement in humanized DMD-disease mouse model" (Publication 142M), is scheduled for presentation on Monday, March 9, 2026.
Precision BioSciences (Nasdaq: DTIL) received a U.S. FDA Study May Proceed notification for its PBGENE-DMD IND, enabling IRB activities and clinical site activation for the FUNCTION-DMD Phase 1/2 study.
PBGENE-DMD is a one-time in vivo gene excision therapy targeting mutations between exons 45–55 (≈60% of DMD patients) intended to restore near full-length dystrophin (~80% of full length). The company plans a March virtual event with KOLs and patient advocates and aims to activate the first U.S. clinical site in H1 2026.
Precision BioSciences (Nasdaq: DTIL) outlined 2026 strategic priorities focused on advancing two clinical-stage gene editing programs: PBGENE-HBV (Phase 1/2a ELIMINATE-B) with dose-finding cohorts ongoing and additional biopsy data expected in H1 2026, and PBGENE-DMD with IND clearance expected in Q1 2026 and first dosing planned for late-Q1/early-Q2 2026 with initial multi-patient data expected by year-end 2026. The company reported unaudited $137 million in cash, cash equivalents, and restricted cash as of December 31, 2025, which management expects to fund key data milestones through 2028. Partnered programs include ECUR-506 (iECURE) and azer-cel (Imugene, TG Therapeutics), and Precision received an $8 million milestone in Q4 2025.